Search results
Intra-Cellular Therapies (NASDAQ:ITCI) PT Raised to $90.00
ETF DAILY NEWS· 4 days agoIntra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) had its price target boosted by Needham & Company LLC from $82.00 to $90.00 in a research note ...
Intra-Cellular Therapies (NASDAQ:ITCI) Given New $96.00 Price Target at Mizuho
ETF DAILY NEWS· 5 days agoThe Goldman Sachs Group upped their target price on shares of Intra-Cellular Therapies from $67.00 to $77.00 and gave the stock a neutral rating in a research note ...
Intra-Cellular Therapies (NASDAQ:ITCI) Rating Reiterated by Cantor Fitzgerald
ETF DAILY NEWS· 2 days agoCantor Fitzgerald’s price objective indicates a potential upside of 66.37% from the stock’s previous close. Several other equities analysts have also weighed in on the company ...
As ketamine therapy booms, industry insiders worry about patient safety
Market Watch· 3 days agoThe incident raises broader questions about at-home ketamine therapy, the doctors wrote. Guidelines...
Weight loss drugs like Wegovy have taken the country by storm. But who can afford them?
USA TODAY· 3 days agoPatients like Price are struggling to afford a blockbuster class of weight-loss medications called...
Investing in Taysha Gene Therapies Inc
Knox Daily· 6 days agoB now holds 16,466,667 shares, worth roughly $37.38 million. Piper Sandler initiated its Taysha Gene Therapies Inc [TSHA] rating to an Overweight in a research note published ...
Pfizer hemophilia gene therapy arrives in US to uncertain future
BioPharma Dive via Yahoo Finance· 2 days ago“The handwriting is on the wall regarding Roctavian,” Piper Sandler analyst Christopher Raymond...
Intra-Cellular Therapies Inc [ITCI] Insider Activity: An Update for Investors – Knox Daily
Knox Daily· 6 days agoRobert W. Baird initiated its Intra-Cellular Therapies Inc [ITCI] rating to an Outperform in a research note published on January 03, 2024; the price target ...
Taysha Gene Therapies Inc (TSHA) Shares Rise Despite Market Challenges – News Heater
NewsHeater· 4 days agoTaysha Gene Therapies Inc (NASDAQ: TSHA) has seen a rise in its stock price by 2.85 in relation to its previous close of 2.46. Is It Worth Investing in Taysha Gene Therapies ...
Insider Selling: Mates Sharon, Intra-Cellular Therapies Inc [ITCI] Chairman, President & CEO...
Knox Daily· 3 days agoUpon closing the transaction, the insider’s holdings decreased to 7,345 shares, worth approximately $0.0. As published in their initiating research note from Robert W. Baird ...